Who are Hyalein Mini Ophthalmic solution's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): New PEG based artificial tear.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/hyalein-mini-ophthalmic-solution.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Hyalein Mini Ophthalmic solution — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hyalein Mini Ophthalmic solution (Hyalein Mini Ophthalmic solution) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Artificial tear / Lubricating ophthalmic agent. Area: Ophthalmology.

phase 3 Artificial tear / Lubricating ophthalmic agent Ocular surface (non-receptor mediated) Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Hyalein Mini Ophthalmic solution (Hyalein Mini Ophthalmic solution) — Otsuka Pharmaceutical Co., Ltd.. Hyalein Mini is a hyaluronic acid-based ophthalmic solution that lubricates and protects the ocular surface.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Hyalein Mini Ophthalmic solution TARGET	Hyalein Mini Ophthalmic solution	Otsuka Pharmaceutical Co., Ltd.	phase 3	Artificial tear / Lubricating ophthalmic agent	Ocular surface (non-receptor mediated)
New PEG based artificial tear	New PEG based artificial tear	Bp Consulting, Inc	marketed	Artificial tear / Lubricating ophthalmic agent

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Artificial tear / Lubricating ophthalmic agent class)

Bp Consulting, Inc · 1 drug in this class
Otsuka Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Hyalein Mini Ophthalmic solution — Competitive Intelligence Brief. https://druglandscape.com/ci/hyalein-mini-ophthalmic-solution. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing